Seagen Says FDA Grants Priority Review For Supplemental Biologics License Application (SBLA) Of PADCEV (Enfortumab Vedotin-ejfv) With KEYTRUDA (Pembrolizumab) For First-Line Treatment Of Advanced Bladder Cancer
西根说，美国食品药品管理局优先审查PADCEV（Enfortumab vedotin-ejfV）的补充生物制剂许可证申请（SBLA），使用KEYTRUDA（Pembrolizumab）对晚期膀胱癌进行一线治疗